Present status of statin therapy
Abstract Statins are cardioprotective agents that reduce the adverse effects of increased low-density lipoprotein cholesterol (LDL-C) levels. For significantly dyslipidemic persons, who are at higher cardiovascular risk, combined statin therapy substantially reduces the mortality risk, thus potentia...
Gespeichert in:
| Veröffentlicht in: | Trends in cardiovascular medicine 2015-04, Vol.25 (3), p.216-225 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 225 |
|---|---|
| container_issue | 3 |
| container_start_page | 216 |
| container_title | Trends in cardiovascular medicine |
| container_volume | 25 |
| creator | Opie, Lionel H., MD, DPhil |
| description | Abstract Statins are cardioprotective agents that reduce the adverse effects of increased low-density lipoprotein cholesterol (LDL-C) levels. For significantly dyslipidemic persons, who are at higher cardiovascular risk, combined statin therapy substantially reduces the mortality risk, thus potentially being an ideal risk-reducing combination with added risk reduction by lifestyle changes. Decisions regarding the initiation of statin therapy for primary prevention where the absolute risk reduction is much less are more difficult, involving LDL-C levels and higher C-reactive protein levels. For significantly dyslipidemic persons, combined intense exercise and statin therapy substantially reduces the mortality risk, thus potentially being an ideal risk-reducing combination. |
| doi_str_mv | 10.1016/j.tcm.2014.10.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1680748694</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1050173814001777</els_id><sourcerecordid>3630116981</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-1bd365847c6cdd5fbdc811c0b449eb24a6ce0409a560f92c512ba1c3924b6c823</originalsourceid><addsrcrecordid>eNp9kU9r3DAQxUVJaP60H6CXsJBLL97MyLIsUyiEkLSFQAJtz0Iej4k2Xnsj2YX99pGzSQM55DQj8XuPmTdCfEFYIqA-Wy1HWi8loErvJYD8IA7RlHkmNRZ7qYcCMixzcyCOYlwBgFYaP4oDWRiQUqpDsbgNHLkfF3F04xQXQ_vU-X4x3nFwm-0nsd-6LvLn53os_l5d_rn4mV3f_Ph1cX6dkcr1mGHd5LowqiRNTVO0dUMGkaBWquJaKqeJQUHlCg1tJalAWTukvJKq1mRkfiy-7nw3YXiYOI527SNx17mehyla1AZKZXSlEnr6Bl0NU-jTdInSKq1mSkwU7igKQ4yBW7sJfu3C1iLYOT67sik-O8c3f6X4kubk2Xmq19z8V7zklYBvO4BTFP88BxvJc0_c-MA02mbw79p_f6OmzveeXHfPW46vW9goLdjf8_3m86GCVMsyfwQV1pID</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1664802871</pqid></control><display><type>article</type><title>Present status of statin therapy</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Opie, Lionel H., MD, DPhil</creator><creatorcontrib>Opie, Lionel H., MD, DPhil</creatorcontrib><description>Abstract Statins are cardioprotective agents that reduce the adverse effects of increased low-density lipoprotein cholesterol (LDL-C) levels. For significantly dyslipidemic persons, who are at higher cardiovascular risk, combined statin therapy substantially reduces the mortality risk, thus potentially being an ideal risk-reducing combination with added risk reduction by lifestyle changes. Decisions regarding the initiation of statin therapy for primary prevention where the absolute risk reduction is much less are more difficult, involving LDL-C levels and higher C-reactive protein levels. For significantly dyslipidemic persons, combined intense exercise and statin therapy substantially reduces the mortality risk, thus potentially being an ideal risk-reducing combination.</description><identifier>ISSN: 1050-1738</identifier><identifier>EISSN: 1873-2615</identifier><identifier>DOI: 10.1016/j.tcm.2014.10.002</identifier><identifier>PMID: 25802224</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Cardiovascular ; Cardiovascular disease ; Child ; Cholesterol ; Drug therapy ; Dyslipidemias - drug therapy ; Heart attacks ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Low density lipoprotein ; Mortality ; Primary Prevention - methods ; Risk Reduction Behavior ; Statins</subject><ispartof>Trends in cardiovascular medicine, 2015-04, Vol.25 (3), p.216-225</ispartof><rights>Elsevier Inc.</rights><rights>2015 Elsevier Inc.</rights><rights>Copyright © 2015 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-1bd365847c6cdd5fbdc811c0b449eb24a6ce0409a560f92c512ba1c3924b6c823</citedby><cites>FETCH-LOGICAL-c436t-1bd365847c6cdd5fbdc811c0b449eb24a6ce0409a560f92c512ba1c3924b6c823</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.tcm.2014.10.002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25802224$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Opie, Lionel H., MD, DPhil</creatorcontrib><title>Present status of statin therapy</title><title>Trends in cardiovascular medicine</title><addtitle>Trends Cardiovasc Med</addtitle><description>Abstract Statins are cardioprotective agents that reduce the adverse effects of increased low-density lipoprotein cholesterol (LDL-C) levels. For significantly dyslipidemic persons, who are at higher cardiovascular risk, combined statin therapy substantially reduces the mortality risk, thus potentially being an ideal risk-reducing combination with added risk reduction by lifestyle changes. Decisions regarding the initiation of statin therapy for primary prevention where the absolute risk reduction is much less are more difficult, involving LDL-C levels and higher C-reactive protein levels. For significantly dyslipidemic persons, combined intense exercise and statin therapy substantially reduces the mortality risk, thus potentially being an ideal risk-reducing combination.</description><subject>Adult</subject><subject>Cardiovascular</subject><subject>Cardiovascular disease</subject><subject>Child</subject><subject>Cholesterol</subject><subject>Drug therapy</subject><subject>Dyslipidemias - drug therapy</subject><subject>Heart attacks</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Low density lipoprotein</subject><subject>Mortality</subject><subject>Primary Prevention - methods</subject><subject>Risk Reduction Behavior</subject><subject>Statins</subject><issn>1050-1738</issn><issn>1873-2615</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9r3DAQxUVJaP60H6CXsJBLL97MyLIsUyiEkLSFQAJtz0Iej4k2Xnsj2YX99pGzSQM55DQj8XuPmTdCfEFYIqA-Wy1HWi8loErvJYD8IA7RlHkmNRZ7qYcCMixzcyCOYlwBgFYaP4oDWRiQUqpDsbgNHLkfF3F04xQXQ_vU-X4x3nFwm-0nsd-6LvLn53os_l5d_rn4mV3f_Ph1cX6dkcr1mGHd5LowqiRNTVO0dUMGkaBWquJaKqeJQUHlCg1tJalAWTukvJKq1mRkfiy-7nw3YXiYOI527SNx17mehyla1AZKZXSlEnr6Bl0NU-jTdInSKq1mSkwU7igKQ4yBW7sJfu3C1iLYOT67sik-O8c3f6X4kubk2Xmq19z8V7zklYBvO4BTFP88BxvJc0_c-MA02mbw79p_f6OmzveeXHfPW46vW9goLdjf8_3m86GCVMsyfwQV1pID</recordid><startdate>20150401</startdate><enddate>20150401</enddate><creator>Opie, Lionel H., MD, DPhil</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20150401</creationdate><title>Present status of statin therapy</title><author>Opie, Lionel H., MD, DPhil</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-1bd365847c6cdd5fbdc811c0b449eb24a6ce0409a560f92c512ba1c3924b6c823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Cardiovascular</topic><topic>Cardiovascular disease</topic><topic>Child</topic><topic>Cholesterol</topic><topic>Drug therapy</topic><topic>Dyslipidemias - drug therapy</topic><topic>Heart attacks</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Low density lipoprotein</topic><topic>Mortality</topic><topic>Primary Prevention - methods</topic><topic>Risk Reduction Behavior</topic><topic>Statins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Opie, Lionel H., MD, DPhil</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Trends in cardiovascular medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Opie, Lionel H., MD, DPhil</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Present status of statin therapy</atitle><jtitle>Trends in cardiovascular medicine</jtitle><addtitle>Trends Cardiovasc Med</addtitle><date>2015-04-01</date><risdate>2015</risdate><volume>25</volume><issue>3</issue><spage>216</spage><epage>225</epage><pages>216-225</pages><issn>1050-1738</issn><eissn>1873-2615</eissn><abstract>Abstract Statins are cardioprotective agents that reduce the adverse effects of increased low-density lipoprotein cholesterol (LDL-C) levels. For significantly dyslipidemic persons, who are at higher cardiovascular risk, combined statin therapy substantially reduces the mortality risk, thus potentially being an ideal risk-reducing combination with added risk reduction by lifestyle changes. Decisions regarding the initiation of statin therapy for primary prevention where the absolute risk reduction is much less are more difficult, involving LDL-C levels and higher C-reactive protein levels. For significantly dyslipidemic persons, combined intense exercise and statin therapy substantially reduces the mortality risk, thus potentially being an ideal risk-reducing combination.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25802224</pmid><doi>10.1016/j.tcm.2014.10.002</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1050-1738 |
| ispartof | Trends in cardiovascular medicine, 2015-04, Vol.25 (3), p.216-225 |
| issn | 1050-1738 1873-2615 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1680748694 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adult Cardiovascular Cardiovascular disease Child Cholesterol Drug therapy Dyslipidemias - drug therapy Heart attacks Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Low density lipoprotein Mortality Primary Prevention - methods Risk Reduction Behavior Statins |
| title | Present status of statin therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T21%3A14%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Present%20status%20of%20statin%20therapy&rft.jtitle=Trends%20in%20cardiovascular%20medicine&rft.au=Opie,%20Lionel%20H.,%20MD,%20DPhil&rft.date=2015-04-01&rft.volume=25&rft.issue=3&rft.spage=216&rft.epage=225&rft.pages=216-225&rft.issn=1050-1738&rft.eissn=1873-2615&rft_id=info:doi/10.1016/j.tcm.2014.10.002&rft_dat=%3Cproquest_cross%3E3630116981%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1664802871&rft_id=info:pmid/25802224&rft_els_id=S1050173814001777&rfr_iscdi=true |